JP2003526660A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003526660A5 JP2003526660A5 JP2001566636A JP2001566636A JP2003526660A5 JP 2003526660 A5 JP2003526660 A5 JP 2003526660A5 JP 2001566636 A JP2001566636 A JP 2001566636A JP 2001566636 A JP2001566636 A JP 2001566636A JP 2003526660 A5 JP2003526660 A5 JP 2003526660A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- composition
- hydroxy
- prostaglandin
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 18
- 125000000217 alkyl group Chemical group 0.000 description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical group 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 125000004043 oxo group Chemical group O=* 0.000 description 6
- -1 prostaglandin compound Chemical class 0.000 description 6
- 150000003180 prostaglandins Chemical class 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 3
- 206010030043 Ocular hypertension Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000011866 long-term treatment Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000002026 docosanoids Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52757300A | 2000-03-16 | 2000-03-16 | |
| US09/527,573 | 2000-03-16 | ||
| US09/730,830 US20010034355A1 (en) | 2000-03-16 | 2000-12-07 | Treatment of ocular hypertension |
| US09/730,830 | 2000-12-07 | ||
| PCT/JP2001/002035 WO2001068072A2 (en) | 2000-03-16 | 2001-03-15 | Composition for use in treatment of ocular hypertension and glaucoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003526660A JP2003526660A (ja) | 2003-09-09 |
| JP2003526660A5 true JP2003526660A5 (enExample) | 2007-12-27 |
Family
ID=27062443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001566636A Pending JP2003526660A (ja) | 2000-03-16 | 2001-03-15 | 高眼圧症および緑内障の治療 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20010056104A1 (enExample) |
| EP (1) | EP1272194A2 (enExample) |
| JP (1) | JP2003526660A (enExample) |
| KR (1) | KR20080012407A (enExample) |
| CN (1) | CN100506232C (enExample) |
| AR (1) | AR029818A1 (enExample) |
| AU (2) | AU4114301A (enExample) |
| BR (1) | BR0109192A (enExample) |
| CA (1) | CA2402597C (enExample) |
| CZ (1) | CZ20023092A3 (enExample) |
| HU (1) | HUP0300391A3 (enExample) |
| IL (1) | IL151683A0 (enExample) |
| MX (1) | MXPA02008967A (enExample) |
| NO (1) | NO20024381L (enExample) |
| NZ (1) | NZ521325A (enExample) |
| RU (1) | RU2002127733A (enExample) |
| TW (1) | TWI286932B (enExample) |
| WO (1) | WO2001068072A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997022689A1 (en) † | 1995-12-18 | 1997-06-26 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
| US20020035148A1 (en) * | 2000-07-20 | 2002-03-21 | Ryuji Ueno | Treatment of ocular hypertension |
| US6713268B2 (en) * | 2001-06-26 | 2004-03-30 | Allergan, Inc. | Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation |
| EP1411950A2 (en) * | 2001-07-31 | 2004-04-28 | Sucampo AG | Treatment of ocular hypertension and glaucoma |
| AU2003215820A1 (en) * | 2002-03-28 | 2003-10-13 | Sucampo Ag | Method for treating ocular hypertension and glaucoma |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3876050T2 (de) * | 1987-09-18 | 1993-03-25 | Ueno Seiyaku Oyo Kenkyujo Kk | Okulare hypotensivagenzien. |
| ES2213504T1 (es) * | 1988-09-06 | 2004-09-01 | Pfizer Health Ab | Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular. |
| US5321128A (en) * | 1988-09-06 | 1994-06-14 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| CA2039420C (en) * | 1990-04-04 | 1996-12-10 | Ryuji Ueno | Treatment of cataract with 15-keto-prostaglandin compounds |
| AU687906B2 (en) * | 1993-12-15 | 1998-03-05 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
| US6011062A (en) * | 1994-12-22 | 2000-01-04 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| WO1997023225A1 (en) * | 1995-12-22 | 1997-07-03 | Alcon Laboratories, Inc. | Combinations of dp and fp type prostaglandins for lowering iop |
| US6232344B1 (en) * | 1997-12-22 | 2001-05-15 | Alcon Laboratories, Inc. | 13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension |
| ATE245451T1 (de) * | 1998-04-07 | 2003-08-15 | Alcon Lab Inc | Xanthangummi enthaltende gelbildende ophthalmische zusammensetzungen |
-
2001
- 2001-03-15 HU HU0300391A patent/HUP0300391A3/hu unknown
- 2001-03-15 CA CA2402597A patent/CA2402597C/en not_active Expired - Fee Related
- 2001-03-15 AU AU4114301A patent/AU4114301A/xx active Pending
- 2001-03-15 AU AU2001241143A patent/AU2001241143B2/en not_active Ceased
- 2001-03-15 BR BR0109192-1A patent/BR0109192A/pt not_active Application Discontinuation
- 2001-03-15 CZ CZ20023092A patent/CZ20023092A3/cs unknown
- 2001-03-15 CN CNB018093396A patent/CN100506232C/zh not_active Expired - Fee Related
- 2001-03-15 RU RU2002127733/15A patent/RU2002127733A/ru unknown
- 2001-03-15 JP JP2001566636A patent/JP2003526660A/ja active Pending
- 2001-03-15 NZ NZ521325A patent/NZ521325A/en not_active IP Right Cessation
- 2001-03-15 IL IL15168301A patent/IL151683A0/xx not_active IP Right Cessation
- 2001-03-15 EP EP01912374A patent/EP1272194A2/en not_active Ceased
- 2001-03-15 MX MXPA02008967A patent/MXPA02008967A/es active IP Right Grant
- 2001-03-15 WO PCT/JP2001/002035 patent/WO2001068072A2/en not_active Ceased
- 2001-03-15 KR KR1020087002403A patent/KR20080012407A/ko not_active Ceased
- 2001-03-16 AR ARP010101231A patent/AR029818A1/es unknown
- 2001-03-16 TW TW090106162A patent/TWI286932B/zh not_active IP Right Cessation
- 2001-03-27 US US09/817,046 patent/US20010056104A1/en not_active Abandoned
-
2002
- 2002-09-13 NO NO20024381A patent/NO20024381L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4475871B2 (ja) | 降圧脂質（プロスタグランジン誘導体）およびチモロールの組成物ならびにその使用方法 | |
| RU2002103597A (ru) | Композиция для лечения нарушений внешней секреции | |
| JP4226650B2 (ja) | 医薬としてのシクロペンタンヘプタン（エン）酸，２―ヘテロアリールアルケニル誘導体 | |
| CN101132797B (zh) | 治疗外周血管病的方法和组合物 | |
| JP2003504397A5 (enExample) | ||
| RU2003134150A (ru) | Замещенные карбоновыми кислотами оксазоловые производные в качестве ppar-альфа и гамма-активаторов при лечении диабета | |
| US6476074B1 (en) | Method and composition for treatment of erectile dysfunction | |
| BRPI0012387B1 (pt) | uso 13,14-diidro-15-ceto-16,16-diflúor-prostaglandina e2, 13,14-diidro-15-ceto-16,16-diflúor-prostaglandina f2a-metil éster, 11-dehidroxi-13,14-diidro-15-ceto-16,16-diflúor-prostaglandina e1 e 13,14-diidro-15-ceto-16,16-diflúor-prostaglandina e1 na indução de secreção lacrimal em um paciente com distúrbios envolvendo hipossecreção lacrimal | |
| JPH11505802A (ja) | 高眼圧処置剤としてのシクロペンタンヘプタン（エン）酸，２−ヘテロアリールアルケニル誘導体 | |
| JP6408426B2 (ja) | 胃腸障害処置用プロスタグランジン誘導体 | |
| JP2006513232A5 (enExample) | ||
| US6562868B1 (en) | Method for treatment of female sexual dysfunction | |
| JP2004504350A (ja) | 高眼圧症および緑内障処置用組成物 | |
| JP2003526660A5 (enExample) | ||
| JP2010502568A (ja) | 消化管の重炭酸分泌を促進するための方法および組成物 | |
| JP2006506381A5 (enExample) | ||
| JP2001521487A (ja) | 医薬としてのシクロペンタン（エン）のホスフィニルオキシアルキルおよびホスホンアミドアルキル誘導体の使用 | |
| AU2001239551B2 (en) | Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof | |
| JP5224625B2 (ja) | 眼科手術において眼圧を制御するための組成物 | |
| TWI501769B (zh) | 治療黃斑部病變用組成物 | |
| TWI403324B (zh) | 醫藥組成物 | |
| RU2002127733A (ru) | Способ лечения или профилактики повышенного глазного давления и глаукомы, фармацевтическая композиция и способ получения соединения простагландинов | |
| JP2004538306A5 (enExample) | ||
| RU2488398C2 (ru) | Фармацевтическая комбинация опиоида и простагландинового соединения | |
| CN108685929A (zh) | 用于治疗具有腹泻的肠易激综合征的方法 |